License and Asset Acquisitions - Schedule of IPR&D Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development	$ 75	$ 23,380	$ 3,600
Seralutinib
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development	0	5,000	0
GB004
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development	0	15,000	0
GB1275
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development	0	0	1,000
Other preclinical programs
Acquired Finite-Lived Intangible Assets [Line Items]
Total in process research and development	$ 75	$ 3,380	$ 2,600